LIVE WEBINAR: Tuesday, June 23, 2020, 7:00 PM – 8:00 PM ET

Data + Perspectives: Clinical Investigators Explore the Biology Underlying the Role of PARP Inhibition in the Management of Common Cancers

Join Dr Neil Love and a panel of clinical investigators as they explore the science and application of PARP inhibitors in cancer therapy.

This interactive webinar will include polling, case studies and panel discussions as well as questions from the audience throughout the program.

Join us Tuesday, June 23, for the live webinar
7:00 PM – 8:00 PM ET
1 AMA PRA Category 1 Credit™

Complimentary Registration
A link to the event will be provided after registration.

A full library of presentation slides will also be made available for those who participate in this live webinar.
 
 
Faculty

Maha Hussain, MD, FACP, FASCO
Genevieve Teuton Professor of Medicine 
Division of Hematology/Oncology
Deputy Director 
Robert H Lurie Comprehensive Cancer Center
Northwestern University Feinberg
School of Medicine
Chicago, Illinois

Ursula Matulonis, MD 
Chief, Division of Gynecologic Oncology 
Brock-Wilson Family Chair 
Dana-Farber Cancer Institute 
Professor of Medicine 
Harvard Medical School  
Boston, Massachusetts 


Philip A Philip, MD, PhD, FRCP 
Kathryn Cramer Endowed Chair
in Cancer Research 
Professor of Oncology and Pharmacology 
Leader, GI and Neuroendocrine Oncology 
Karmanos Cancer Institute 
Wayne State University 
Detroit, Michigan 

Hope S Rugo, MD 
Professor of Medicine 
Director, Breast Oncology and
Clinical Trials Education 
University of California, San Francisco
Helen Diller Family Comprehensive
Cancer Center
San Francisco, California 

Moderator

Neil Love, MD
Research To Practice
Miami, Florida


This symposium is accredited by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck. This is not an official program of the American Association for Cancer Research Annual Meeting.

Target Audience
This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists and scientific and research professionals involved in basic, translational and clinical cancer research or treatment.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Comprehend how DNA damage repair (DDR) pathway abnormalities can be targeted via PARP inhibition to elicit benefit in cancer therapy.
  • Consider the correlation between BRCA1/2 mutations and the development of hereditary cancers, and counsel patients with these genetic abnormalities regarding their long-term outlook and therapeutic options.
  • Appraise available guideline recommendations and consensus statements regarding the indications and evidence-based modalities for genetic testing in ovarian, breast, pancreatic and prostate cancer, and use the results of these assessments to guide treatment planning with PARP inhibitors, including as part of clinical trial accrual.
  • Appreciate available clinical trial data with FDA-approved PARP inhibitors for patients with ovarian cancer in different disease settings, and safely integrate these agents into routine clinical care.
  • Evaluate the recent FDA approval of PARP inhibitors for patients with HER2-negative metastatic breast cancer harboring a germline BRCA mutation, and discern how these agents can be appropriately and safely integrated into routine clinical practice.
  • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among commercially available and investigational PARP inhibitors to better understand the activity and toxicity of these agents.
  • Recall the recent FDA approval of PARP inhibition as maintenance therapy for patients with metastatic pancreatic cancer with BRCA mutations whose disease has not progressed on first-line platinum-based chemotherapy, and identify those for whom this strategy is appropriate.
  • Describe the rationale for testing patients with metastatic prostate cancer for mutations in homologous DNA recombination repair genes, and advise those found to harbor these genetic abnormalities on outcomes from clinical trials evaluating PARP inhibition.
  • Describe mechanisms of acquired tumor resistance to PARP inhibitors, and identify investigational combination therapeutic opportunities to circumvent this process.
  • Understand the biologic rationale for the design of ongoing clinical trials evaluating novel therapeutic approaches with PARP inhibitors for patients with DDR deficiencies, and use this knowledge to recommend appropriate research opportunities.

CME Credit Form
A CME credit form link will be emailed to each participant after the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.